News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Antitope Announces EpiScreen Collaboration With ISU ABXIS CO., LTD

11/12/2008 3:36:47 PM

Cambridge, UK - 12 November 2008 - Antitope Ltd. ("Antitope") today announced a research collaboration with the Korean biopharmaceutical company Isu Abxis Co., Ltd ("Isu Abxis") in which Antitope will apply its proprietary EpiScreenTM technology to profile the immunogenicity of Isu Abxis's therapeutic monoclonal antibodies.

"We are very pleased to be working with Isu Abxis whom we recognize as a world-class company for development and commercialization of therapeutic antibodies," said Dr Matthew Baker, Chief Scientific Officer and co-founder of Antitope. "We look forward to assisting ISU Abxis in selecting antibodies with low immunogenicity potential arising from their pioneering R&D programmes."

Dr. Sang-Ho Park, Head of Drug Development at Isu Abxis adds, "Immunogenicity is a critical issue in the development of biologics, even when dealing with fully human sequence-derived proteins or antibodies. Antitope technologies in identifying problematic proteins will be of great benefit in screening out candidates that pose potential obstacles in safety."

About Antitope

Antitope Ltd. is a Cambridge UK-based biotechnology company specializing in immunogenicity testing and the engineering of therapeutic antibodies/proteins to reduce immunogenicity. Antitope's proprietary EpiScreenTM technology uses human T cells to measure the immunogenicity potential of biopharmaceuticals. Antitope's Composite Human AntibodyTM and Composite ProteinTM technologies deliver novel therapeutic antibodies and proteins with very low immunogenicity potential through the avoidance of T cell epitopes. Antitope are a privately-held company and have established multiple commercial relationships with leading biotechnology and pharmaceutical companies. For further information on Antitope visit

About Isu Abxis

Isu Abxis is based in Seoul, Korea and is part of the Isu Group. Founded in 2001, its major focus is the development of therapeutic proteins, mostly antibodies. The main target areas are cancer and inflammatory diseases. Isu Abxis is the first Korean company to successfully manufacture and register a therapeutic antibody product, Clotinab, and currently has sales partners in more than 30 countries worldwide. For more information on Isu Abxis, visit

Read at

Related News

comments powered by Disqus